Your browser is no longer supported. Please, upgrade your browser.
Settings
VTGN [NASD]
VistaGen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own0.10% Shs Outstand143.76M Perf Week-1.92%
Market Cap297.53M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float109.42M Perf Month-13.19%
Income-16.40M PEG- EPS next Q-0.04 Inst Own53.40% Short Float5.69% Perf Quarter-12.82%
Sales0.60M P/S495.89 EPS this Y44.20% Inst Trans- Short Ratio1.83 Perf Half Y149.97%
Book/sh1.16 P/B1.76 EPS next Y-8.70% ROA-46.20% Target Price- Perf Year385.71%
Cash/sh0.72 P/C2.85 EPS next 5Y- ROE-75.50% 52W Range0.35 - 3.18 Perf YTD5.15%
Dividend- P/FCF- EPS past 5Y45.60% ROI- 52W High-35.85% Beta0.79
Dividend %- Quick Ratio35.20 Sales past 5Y- Gross Margin- 52W Low482.86% ATR0.15
Employees9 Current Ratio35.20 Sales Q/Q- Oper. Margin- RSI (14)44.01 Volatility6.80% 7.10%
OptionableNo Debt/Eq0.00 EPS Q/Q52.10% Profit Margin- Rel Volume0.36 Prev Close2.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.41M Price2.04
Recom1.50 SMA20-4.68% SMA50-7.42% SMA20057.33% Volume1,238,832 Change0.99%
Feb-18-21Initiated Jefferies Buy $6
Jan-04-21Upgrade William Blair Mkt Perform → Outperform
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17Initiated Maxim Group Buy $4
Mar-31-21 10:30PM  
Mar-22-21 08:30AM  
Mar-16-21 07:46AM  
Mar-11-21 08:30AM  
08:17AM  
Feb-18-21 12:00PM  
10:02AM  
Feb-15-21 08:05AM  
Feb-11-21 05:55PM  
04:30PM  
Jan-06-21 08:00AM  
Dec-30-20 09:00AM  
Dec-22-20 04:01PM  
Dec-18-20 06:25AM  
Dec-17-20 04:01PM  
Dec-10-20 08:30AM  
Dec-01-20 08:30AM  
Nov-19-20 10:58AM  
Nov-16-20 03:07AM  
Nov-12-20 05:25PM  
08:30AM  
Oct-27-20 08:17AM  
Oct-14-20 08:30AM  
Sep-03-20 08:30AM  
Aug-31-20 05:00PM  
Aug-27-20 08:30AM  
Aug-13-20 04:30PM  
Aug-10-20 08:30AM  
Aug-05-20 08:12AM  
Jul-23-20 08:00AM  
Jun-29-20 05:16PM  
Jun-25-20 08:00AM  
May-27-20 08:00AM  
May-18-20 08:05AM  
Apr-29-20 10:35AM  
Apr-28-20 09:15AM  
Mar-25-20 09:00AM  
Feb-20-20 08:30AM  
Feb-13-20 04:30PM  
Feb-11-20 08:30AM  
Jan-30-20 08:30AM  
Dec-19-19 08:30AM  
Dec-11-19 10:06AM  
Dec-10-19 08:30AM  
Dec-06-19 09:26AM  
Nov-20-19 09:31AM  
Nov-15-19 10:09AM  
10:02AM  
Nov-14-19 07:30AM  
Nov-07-19 06:30AM  
Nov-01-19 01:45PM  
Oct-28-19 08:30AM  
Oct-18-19 10:23AM  
Oct-08-19 08:30AM  
Aug-15-19 08:30AM  
Aug-13-19 04:30PM  
Jul-23-19 08:30AM  
Jun-27-19 08:11AM  
Jun-25-19 04:15PM  
Jun-20-19 09:30AM  
May-30-19 08:30AM  
May-07-19 08:30AM  
May-02-19 12:13PM  
07:00AM  
Apr-27-19 09:55AM  
Apr-03-19 08:30AM  
Apr-01-19 08:30AM  
Mar-28-19 08:30AM  
Mar-14-19 08:30AM  
Mar-13-19 08:30AM  
Mar-07-19 09:35AM  
Feb-27-19 12:30PM  
Feb-26-19 09:00AM  
Feb-25-19 04:03PM  
Feb-19-19 08:30AM  
Feb-14-19 12:03PM  
Feb-13-19 08:30AM  
07:49AM  
Feb-12-19 04:49PM  
Feb-05-19 08:30AM  
Jan-31-19 08:30AM  
Jan-15-19 08:30AM  
Dec-27-18 08:30AM  
Dec-21-18 12:33PM  
Nov-29-18 08:30AM  
Nov-15-18 08:45AM  
Nov-12-18 08:30AM  
Oct-29-18 04:30PM  
10:17AM  
Oct-25-18 09:00AM  
Oct-22-18 08:30AM  
Oct-15-18 08:30AM  
Oct-11-18 03:31PM  
Oct-04-18 09:45AM  
08:00AM  
Oct-03-18 08:48AM  
08:30AM  
Sep-13-18 08:30AM  
Sep-06-18 06:57AM  
Aug-14-18 04:49PM  
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Underdown Brian J.DirectorMar 19Option Exercise1.502,5003,7502,500Mar 22 07:06 PM
SAXE JON SDirectorMar 19Option Exercise1.502,5003,7505,751Mar 22 07:03 PM
SAXE JON SDirectorAug 21Buy0.6930,00020,70050,000Aug 24 04:31 PM